Equities

Eurobio Scientific SA

Eurobio Scientific SA

Actions
  • Price (EUR)24.65
  • Today's Change-0.20 / -0.80%
  • Shares traded--
  • 1 Year change+61.75%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8986102
Total Receivables, Net324054
Total Inventory212216
Prepaid expenses1.010.570.47
Other current assets, total0.870.440.64
Total current assets144149174
Property, plant & equipment, net121310
Goodwill, net11611618
Intangibles, net37393.59
Long term investments------
Note receivable - long term------
Other long term assets6.99144.46
Total assets316331210
LIABILITIES
Accounts payable13136.97
Accrued expenses6.109.666.58
Notes payable/short-term debt00.661.08
Current portion long-term debt/capital leases15154.15
Other current liabilities, total191917
Total current liabilities535736
Total long term debt869911
Total debt10111416
Deferred income tax------
Minority interest------
Other liabilities, total2.191.792.09
Total liabilities14115849
SHAREHOLDERS EQUITY
Common stock3.503.633.63
Additional paid-in capital344040
Retained earnings (accumulated deficit)138129117
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.000.000.00
Total equity175173161
Total liabilities & shareholders' equity316331210
Total common shares outstanding111111
Treasury shares - common primary issue0.020.010.01
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.